ChemoCentryx

Healthcare biotech drug development pharma

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

Revenue(FY, 2017)

$82.5 M

Market capitalization(2018-08-16)

$551.6 M

Type

Public

Mountain View, US

Founded

1997

Size (employees)

62 (est)

Website

chemocentryx.com

ChemoCentryx was founded in 1997 and is headquartered in Mountain View, US

Report incorrect company information

Key People/Management at ChemoCentryx

Thomas J. Schall

President, Chief Executive Officer and Chairman of the Board

Markus J. Cappel

Chief Business Officer and Treasurer

Report incorrect company information

ChemoCentryx Office Locations

Open Map View

ChemoCentryx has an office in Mountain View

Mountain View, US (HQ)

850 Maude Avenue

Show all (1)

Report incorrect company information

ChemoCentryx Financials and Metrics

ChemoCentryx Revenue

ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017

Summary

USD
Net income (Q2, 2018)	(16.3 m)
EBIT (Q2, 2018)	(17.3 m)
Market capitalization (16-Aug-2018)	551.6 m
Closing stock price (16-Aug-2018)	11
Cash (30-Jun-2018)	68.8 m
EV	497.6 m

ChemoCentryx's current market capitalization is $551.6 m.

Income Statement

Annual

USD	FY, 2016	FY, 2017
Revenue	11.9 m	82.5 m
General and administrative expense	14.7 m	16.5 m
R&D expense	37.9 m	49.5 m
Operating expense total	52.7 m	66 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Revenue							2.8 m	4.3 m	8.2 m	9 m	9.5 m
General and administrative expense	3.4 m	3.5 m	3.7 m	3.6 m	3.8 m	4.1 m	3.9 m	3.2 m	4.6 m		4.7 m	9.4 m
R&D expense	9 m	7.5 m	8.4 m	8.6 m	7.9 m	11.2 m	9.1 m	8.4 m	10 m		14.7 m	32.5 m
Operating expense total	12.4 m	11.1 m	12.1 m	12.2 m	11.7 m	15.3 m	12.9 m	11.6 m	14.5 m	15.9 m	19.4 m	41.9 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	10.3 m	16.1 m	12.8 m	12 m	40 m
Accounts Receivable				30.2 m	51.1 m
Inventories	596 k	972 k	757 k	722 k
Current Assets	134.3 m	74.3 m	72 m	148.7 m	179.8 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Cash	13.1 m	20.9 m	25.4 m	11.6 m	14.6 m	13.4 m	21.9 m	13.9 m	19 m	18 m	30.6 m	68.8 m
Accounts Receivable							175 k	120 k	30.2 m	530 k wdxefcqufszuzezftuxetqsqxt	1.7 m	164 k
Inventories										1.3 m
Current Assets	100.8 m	86.1 m	76.1 m	71.4 m	74.2 m	65.2 m	127 m	122.7 m	119.9 m	122.4 m	149.8 m	184.9 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(38.7 m)	(46.9 m)	(47.3 m)	(40 m)	17.9 m
Depreciation and Amortization	576 k	543 k	477 k	348 k	418 k
Inventories
Accounts Payable	159 k	(161 k)	(73 k)	(4 k)	729 k

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Net Income	(12.3 m)	(10.9 m)	(12 m)	(12.1 m)	(11.6 m)	(15.2 m)	(10 m)	(7.1 m)	(6 m)	(6.6 m)	(9.4 m)	(16.3 m)
Depreciation and Amortization											111 k	227 k
Inventories										1.3 m
Accounts Payable	690 k	1 m	809 k	1 m	615 k	1.3 m	513 k	840 k	819 k	1.4 m	(951 k)	(378 k)